Get started

MBRX

MBRX Annamycin Fast Track and Orphan Drug Designation from FDAMoleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which is at all time low now. 52 Week Range 1.64 - 8.78 My price target is $3.8
NASDAQ:MBRXLong
by TopgOptions
Is $MBRX- The Best Biotech with the most upside Potential Is $MBRX- The Best Biotech with the most upside Potential Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and $MBRX break through with STAT3 inhibitors is a game-changer for treating cancer patients. As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term.. One you might want to research and stick away in your IRA .. As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
NASDAQ:MBRXLong
by InvisbleHand
1